PAVmed Inc. (NASDAQ:PAVM) Short Interest Down 25.8% in February

PAVmed Inc. (NASDAQ:PAVM) was the target of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 262,500 shares, a decrease of 25.8% from the January 31st total of 354,000 shares. Based on an average daily volume of 211,600 shares, the short-interest ratio is presently 1.2 days. Approximately 2.7% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets reduced their price objective on PAVmed from $21.00 to $19.00 and set a “buy” rating for the company in a research note on Monday, December 9th.

PAVmed Price Performance

PAVmed stock traded down $0.03 during mid-day trading on Tuesday, hitting $0.66. The company’s stock had a trading volume of 94,556 shares, compared to its average volume of 102,852. The firm’s 50 day moving average is $0.67 and its 200 day moving average is $0.93. The company has a market cap of $7.31 million, a PE ratio of -0.15 and a beta of 1.19. PAVmed has a 52-week low of $0.57 and a 52-week high of $3.16.

Institutional Investors Weigh In On PAVmed

A hedge fund recently raised its stake in PAVmed stock. First Manhattan CO. LLC. raised its position in shares of PAVmed Inc. (NASDAQ:PAVM) by 16.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 700,000 shares of the company’s stock after purchasing an additional 100,000 shares during the period. First Manhattan CO. LLC. owned 6.32% of PAVmed worth $439,000 as of its most recent SEC filing. Institutional investors own 19.93% of the company’s stock.

About PAVmed

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.